FINWIRES · TerminalLIVE
FINWIRES

Babcock & Wilcox Prices $200 Million Common Stock Offering

By

Babcock & Wilcox Enterprises (BW) said Friday it priced a public offering of about 10.8 million common shares at $18.50 per share, for expected gross proceeds of about $200 million.

Underwriters have been granted a 30-day option to purchase up to an additional 15% of the offered shares.

Proceeds from the offering, expected to close Monday, will be used to pay down debt, fund equipment production and support growth plans, such as AI data center projects and potential acquisitions.

Shares of Babcock fell more than 9% in recent premarket activity Friday.

Price: $19.22, Change: $-1.97, Percent Change: -9.28%

Related Articles

Australia

Update: Market Chatter: Magnum Ice Cream Shares Rise as Blackstone, CD&R Weigh Bids for Company

(Updates to include the stock movement in the headline, the first paragraphs.)Magnum Ice Cream (MICC) shares rose over 16% in recent premarket trading after reports that Blackstone (BX) and Clayton, Dubilier & Rice are in the early stages of considering bids for the company, Reuters reported Friday, citing unnamed sources familiar with the matter.The private equity firms are monitoring the company's share price and awaiting summer performance data before making a decision, the news outlet reported, citing the sources.Magnum is also attracting interest from other buyout group, as prospective investors view the producer as a turnaround candidate that could increase profitability through cost reductions, the report said.Blackstone, CD&R and Magnum Ice Cream did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $17.56, Change: $+2.54, Percent Change: +16.91%

$BX$MICC
Australia

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Australia

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH